Brain Tumors

Brain tumor care advances with IDH-targeted therapies and the maturing immunotherapy landscape. The session covers vorasidenib in IDH-mutant glioma (INDIGO phase 3), ivosidenib and combination approaches, glioblastoma post-Stupp with TTFields (Optune), brain metastases management including stereotactic radiosurgery and whole-brain radiation alternatives, CSF ctDNA in CNS lymphoma and metastases, and immunotherapy in CNS tumours (the limited but emerging evidence). Discussion addresses pediatric brain tumours including diffuse midline glioma and H3K27M alterations, MGMT methylation and temozolomide, glioneural tumours, the role of awake craniotomy and intraoperative MRI, and emerging targets including CAR-T against EGFR-VIII and GD2.